Hopkins Institutional Review Board approved this research protocol.
From each patient's clinical record, we abstracted demographic and clinical information and laboratory test results obtained within 60 days after the renal biopsy. Proteinuria was measured by 24-h urine protein collection or was estimated by spot urine protein-to-creatinine ratio. Patients were divided into those with HIV-1 RNA levels of !400 copies/mL and those with HIV-1 RNA levels of у400 copies/mL. Renal outcome was abstracted from each patient's record from the time of renal biopsy to the end of the study period or the last available clinical encounter. Serological findings and classic histopathologic features-including collapsing glomerulopathy, tubulointerstitial inflammation, and podocyte effacement-established HIVAN [5] . Predominance of histopathologic features other than those classic for HIVAN defined non-HIVAN cases. The frequency of each specific histopathologic condition was then tabulated.
Statistical analyses were performed using Stata software, version 9 (Stata). For normally distributed continuous variables, mean values were compared using Student's t test, whereas Wilcoxon rank-sum test was performed for markedly skewed data. The x 2 test was used for comparing discrete data. Association between clinical variables and HIVAN was measured using logistic regression. ORs were obtained from univariate and multivariate models. Sensitivity, specificity, and positive and negative predictive values of an HIV-1 RNA level у400 copies/mL for HIVAN were calculated with use of the biopsy report as the criterion standard.
Kaplan-Meier survival analysis was employed for calculating cumulative probability of renal survival. Patients who began chronic dialysis within 30 days after renal biopsy were excluded from this analysis. Time until initiation of chronic dialysis defined renal survival. Renal survival rates were compared using the log-rank test.
Results. Of 86 patients, 23 had viral loads of !400 copies/ mL, and 63 had viral loads of у400 copies/mL ( (table 2 ). An HIV-1 RNA level of у400 P p .132 copies/mL was highly sensitive for HIVAN (sensitivity, 95.8%; negative predictive value, 95.7%), but it was nonspecific (specificity, 35.5%) (table 3).
We found a wide variety of renal pathologic conditions in both viral load groups (table 4). Among patients with viral loads of !400 copies/mL, only 1 patient had HIVAN. In this group, the most common renal lesion was hypertensive vascular disease, followed by noncollapsing focal segmental glomerulosclerosis. Four patients with viral loads of !400 copies/mL had severe diabetic glomerulosclerosis. Among patients with viral loads у400 copies/mL, 23 had HIVAN. Hypertensive vascular disease was the second most common histopathological condition noted.
The cumulative renal survival rate among all eligible patients was 30.0%. During 2317 days of follow-up (figure 1A), renal survival rate did not differ between the 2 groups ( ). P p .28 However, in subgroup analysis (figure 1B), the renal survival rate for patients with viral loads !400 copies/mL was significantly better than for patients with viral loads у400 copies/ mL and HIVAN (29.5% vs. 10.4%;
). P p .032 Discussion. To our knowledge, our study is the first to measure the predictive value of the HIV-1 RNA level in distinguishing HIVAN from non-HIVAN renal disease. A viral load !400 copies/mL was associated with a low likelihood of HIVAN, consistent with the growing number of studies suggesting the role of renal viral infection in HIVAN development [6] [7] [8] [9] . Conversely, 1 prior study reported biopsy-proven HIVAN in patients with undetectable viral loads [4] . Of the 42 patients with HIVAN in that study, 5 had undetectable HIV-1 RNA levels at the time of renal diagnosis. These patients may have had advanced renal failure due to HIVAN, which antiretroviral therapy could not reverse. Our 1 patient with a low viral load and HIVAN had substantial renal dysfunction (serum creatinine level, 3.7 mg/dL) and viral loads у400 copies/mL several months before his renal biopsy was performed, during which time he was intermittently adherent to HAART. At the time of his biopsy, the patient was experiencing end-stage renal failure, with his biopsy showing near-global glomerulosclerosis that was unlikely to improve with HAART.
However, a recent case report of a woman with HIV infection who experienced moderate renal failure and had features of HIVAN detected on biopsy despite the fact that her HIV infection was well treated implies that HIVAN may occur at any time in the course of HIV infection through a pathway independent of HIV renal infection [10] . Alternatively, the biopsy findings in this particular case [10] may represent remnants of treated HIVAN that occurred during a preceding period of significant viremia. Reversal of histological changes may occur as early as 14 weeks after initiation of HAART, although some changes persist despite effective therapy [11] .
As in earlier studies, we found an array of renal lesions in our patients, although the majority of patients had non-HIVAN disease. In fact, hypertensive vascular disease surpassed HIVAN as the single most common biopsy finding among all patients. This observation may reflect an evolving profile of renal diseases affecting HIV-infected patients as a result of systemic nonantiviral effects of HAART or a shift towards more-traditional causes of chronic kidney disease.
Although our 2 groups did not differ with respect to the number of patients with hypertension, a greater proportion of patients with viral loads !400 copies/mL had at least moderateto-severe hypertensive vascular disease pathologically (43.5% vs. 23.8%). This may stem from the groups' differences with respect to HAART exposure [12] [13] [14] . HAART exposure of 12 years in duration has been associated with a 51% increased incidence of systolic hypertension. This risk pattern implies that HAART may directly affect arterial walls, causing isolated systolic hypertension [12] .
A greater proportion of patients with HIV-1 RNA levels !400 copies/mL had diabetic glomerulosclerosis (17.4% vs. 4.8%), presumably as a result of the greater number of patients with diabetes in this group. This difference may arise from differences in HAART exposure [14] [15] [16] . In a 4-year cohort study, men receiving HAART had a 14-fold increased risk of developing diabetes, compared with men without HIV infection [15] . Protease inhibitors, in particular, have been linked to diabetes, with a 5-fold increased incidence of hyperglycemia associated with use of these drugs [17] . This is supported by in vitro and murine studies demonstrating protease inhibitorinduced impairment of the glucose transporter Glut 4 and of glucose sensing in ß-islet cells [18, 19] .
Our study did not show a difference in renal survival based on viral load, likely because the majority of our patients had non-HIVAN renal disease. Having both viral load у400 copies/ mL and HIVAN portended poorer renal prognosis, likely representing poorer overall health in this patient subgroup. Although HAART is associated with a better renal outcome among patients with HIVAN, it has not been shown to benefit patients with non-HIVAN renal disease [4] . Our study lacked sufficient data on the severity of comorbid conditions to include within the renal survival analysis. It would be interesting to determine the effects of these parameters on renal survival in larger cohorts.
Although this study provides a useful measure for differentiating between HIVAN and non-HIVAN renal disease, it is not without limitations. The moderate sample size may have restricted our ability to show clinical differences of interest. Because this was a single-center study comprised primarily of African American patients and a large number of injection drug users, our findings may not reflect findings in the general HIVinfected population. We categorized viral loads using a threshold of 400 copies/mL, because our study included data from as early as 1995, when ultrasensitive HIV-1 RNA assays were Figure 1 . A, Kaplan Meier estimates of renal survival for 19 patients with HIV-1 RNA levels !400 copies/mL, compared with 52 patients with HIV-1 RNA levels у400 copies/mL ( ). B, Kaplan Meier estimates P p .28 of renal survival for 19 patients with HIV-1 RNA levels !400 copies/mL, compared with 23 patients with HIV-1 RNA levels у400 copies/mL and HIV-associated nephropathy ( ). P p .03 not routinely used. It would be useful to assess the relationship between viral load and HIVAN using a receiver operating characteristic curve.
Although no single test other than renal biopsy can definitively diagnose HIVAN, we found that HIVAN is unlikely among patients with HIV-1 RNA levels of !400 copies/mL. We previously reported the limitations of proteinuria, CD4 + cell counts, and renal ultrasound in predicting HIVAN [20, 21] . Therefore, for patients with contraindications to renal biopsy, the combination of clinical history and HIV-1 RNA level of !400 copies/mL may be useful in excluding HIVAN from the list of possible renal diseases. Although HIVAN has traditionally been thought to be the most common renal disease affecting patients with HIV infection, our study suggests that moretraditional causes of renal disease are becoming increasingly common in the era of HAART.
